Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Free Report) insider Matthew Fry acquired 150,000 shares of the business’s stock in a transaction on Thursday, October 10th. The shares were purchased at an average cost of A$0.20 ($0.14) per share, for a total transaction of A$30,450.00 ($20,436.24).
Paradigm Biopharmaceuticals Price Performance
The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.93 and a current ratio of 7.22.
About Paradigm Biopharmaceuticals
Featured Stories
- Five stocks we like better than Paradigm Biopharmaceuticals
- What is the Hang Seng index?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.